LY3938577 not checked

Eli Lilly

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 2 trial completes
Trials
1 active
3 in total · 1 in the EU
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
Tested for
Diabetes Mellitus, Type 2
Main trialPhase 2
“The purpose of this study is to see how well LY3938577 works and how safe it is compared to degludec in people with type 2 diabetes. Participation in the study will last about 26 weeks.”In the company’s words, NCT07215312 on ClinicalTrials.gov

Other drugs for Diabetes Mellitus, Type 2

All 128 drugs for Diabetes Mellitus, Type 2

Coming up1

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials3

TrialPhaseCompletesWhat it tests
Phase 2Active, not recruiting Nov 2026 A Study of LY3938577 in Participants With Type 2 Diabetes Previously Treated With Basal Insulin
Phase 1Completed 28 Jun 2024 A Study to Investigate the Safety and Tolerability of LY3938577 in Healthy Participants and Participants With Type 2 Diabetes Mellitus
Phase 1Completed 3 Oct 2026 A Study of LY3938577 in Healthy Participants and Participants With Type 1 Diabetes Mellitus (T1DM)
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow LY3938577

Following is part of Solo: you see every change to LY3938577 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in